-
1
-
-
0022588467
-
Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor
-
Yamamoto T, Ikawa S, Akiyama T, et al. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature. 1986; 319: 230-234. (Pubitemid 16128786)
-
(1986)
Nature
, vol.319
, Issue.6050
, pp. 230-234
-
-
Yamamoto, T.1
Ikawa, S.2
Akiyama, T.3
-
2
-
-
37049183697
-
Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
-
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL,. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235: 177-182. (Pubitemid 17231334)
-
(1987)
Science
, vol.235
, Issue.4785
, pp. 177-182
-
-
Slamon, D.J.1
Clark, G.M.2
Wong, S.G.3
-
3
-
-
0034327895
-
Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry
-
Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000; 18: 3651-3664.
-
(2000)
J Clin Oncol.
, vol.18
, pp. 3651-3664
-
-
Pauletti, G.1
Dandekar, S.2
Rong, H.3
-
4
-
-
0024337144
-
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
-
Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244: 707-712. (Pubitemid 19147683)
-
(1989)
Science
, vol.244
, Issue.4905
, pp. 707-712
-
-
Slamon, D.J.1
Godolphin, W.2
Jones, L.A.3
Holt, J.A.4
Wong, S.G.5
Keith, D.E.6
Levin, W.J.7
Stuart, S.G.8
Udove, J.9
Ullrich, A.10
Press, M.F.11
-
5
-
-
33745791118
-
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer
-
DOI 10.1016/j.ccr.2006.05.024, PII S1535610806001802
-
Zhou BB, Peyton M, He B, et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell. 2006; 10: 39-50. (Pubitemid 44018087)
-
(2006)
Cancer Cell
, vol.10
, Issue.1
, pp. 39-50
-
-
Zhou, B.-B.S.1
Peyton, M.2
He, B.3
Liu, C.4
Girard, L.5
Caudler, E.6
Lo, Y.7
Baribaud, F.8
Mikami, I.9
Reguart, N.10
Yang, G.11
Li, Y.12
Yao, W.13
Vaddi, K.14
Gazdar, A.F.15
Friedman, S.M.16
Jablons, D.M.17
Newton, R.C.18
Fridman, J.S.19
Minna, J.D.20
Scherle, P.A.21
more..
-
6
-
-
0141615794
-
Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer
-
DOI 10.1373/49.10.1579
-
Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP,. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem. 2003; 49: 1579-1598. (Pubitemid 37194212)
-
(2003)
Clinical Chemistry
, vol.49
, Issue.10
, pp. 1579-1598
-
-
Carney, W.P.1
Neumann, R.2
Lipton, A.3
Leitzel, K.4
Ali, S.5
Price, C.P.6
-
7
-
-
34548562456
-
HER-2/neu diagnostics in breast cancer
-
Carney WP, Leitzel K, Ali S, Neumann R, Lipton A,. HER-2/neu diagnostics in breast cancer. Breast Cancer Res. 2007; 9: 207.
-
(2007)
Breast Cancer Res.
, vol.9
, pp. 207
-
-
Carney, W.P.1
Leitzel, K.2
Ali, S.3
Neumann, R.4
Lipton, A.5
-
8
-
-
0037087535
-
Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer
-
DOI 10.1200/JCO.20.6.1467
-
Lipton A, Ali SM, Leitzel K, et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol. 2002; 20: 1467-1472. (Pubitemid 34260524)
-
(2002)
Journal of Clinical Oncology
, vol.20
, Issue.6
, pp. 1467-1472
-
-
Lipton, A.1
Ali, S.M.2
Leitzel, K.3
Demers, L.4
Chinchilli, V.5
Engle, L.6
Harvey, H.A.7
Brady, C.8
Nalin, C.M.9
Dugan, M.10
Carney, W.11
Allard, J.12
-
9
-
-
0038011944
-
Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen
-
DOI 10.1200/JCO.2003.09.098
-
Lipton A, Ali SM, Leitzel K, et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol. 2003; 21: 1967-1972. (Pubitemid 46606385)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.10
, pp. 1967-1972
-
-
Lipton, A.1
Ali, S.M.2
Leitzel, K.3
Demers, L.4
Harvey, H.A.5
Chaudri-Ross, H.A.6
Brady, C.7
Wyld, P.8
Carney, W.9
-
10
-
-
0034082031
-
Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer
-
Colomer R, Montero S, Lluch A, et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res. 2000; 6: 2356-2362. (Pubitemid 30399203)
-
(2000)
Clinical Cancer Research
, vol.6
, Issue.6
, pp. 2356-2362
-
-
Colomer, R.1
Montero, S.2
Lluch, A.3
Ojeda, B.4
Barnadas, A.5
Casado, A.6
Massuti, B.7
Cortes-Funes, H.8
Lloveras, B.9
-
11
-
-
0036534121
-
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer
-
DOI 10.1200/JCO.2002.07.058
-
Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20: 1800-1808. (Pubitemid 34273269)
-
(2002)
Journal of Clinical Oncology
, vol.20
, Issue.7
, pp. 1800-1808
-
-
Esteva, F.J.1
Valero, V.2
Booser, D.3
Guerra, L.T.4
Murray, J.L.5
Pusztai, L.6
Cristofanilli, M.7
Arun, B.8
Esmaeli, B.9
Fritsche, H.A.10
Sneige, N.11
Smith, T.L.12
Hortobagyi, G.N.13
-
12
-
-
3543146052
-
Monitoring of Serum Her-2/neu Predicts Response and Progression-Free Survival to Trastuzumab-Based Treatment in Patients with Metastatic Breast Cancer
-
DOI 10.1158/1078-0432.CCR-0385-3
-
Kostler WJ, Schwab B, Singer CF, et al. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res. 2004; 10: 1618-1624. (Pubitemid 38435551)
-
(2004)
Clinical Cancer Research
, vol.10
, Issue.5
, pp. 1618-1624
-
-
Kostler, W.J.1
Schwab, B.2
Singer, C.F.3
Neumann, R.4
Rucklinger, E.5
Brodowicz, T.6
Tomek, S.7
Niedermayr, M.8
Hejna, M.9
Steger, G.G.10
Krainer, M.11
Wiltschke, C.12
Zielinski, C.C.13
-
13
-
-
34547097500
-
Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy
-
DOI 10.1002/cncr.22825
-
Sandri MT, Johansson HA, Zorzino L, et al. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy. Cancer. 2007; 110: 509-517. (Pubitemid 47106138)
-
(2007)
Cancer
, vol.110
, Issue.3
, pp. 509-517
-
-
Sandri, M.T.1
Johansson, H.A.2
Zorzino, L.3
Salvatici, M.4
Passerini, R.5
Maisonneuve, P.6
Rocca, A.7
Peruzzotti, G.8
Colleoni, M.9
-
14
-
-
53149107465
-
Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer
-
Ali SM, Carney WP, Esteva FJ, et al. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer. 2008; 113: 1294-1301.
-
(2008)
Cancer.
, vol.113
, pp. 1294-1301
-
-
Ali, S.M.1
Carney, W.P.2
Esteva, F.J.3
-
15
-
-
51149117030
-
Drug insight: Intracellular inhibitors of HER2-clinical development of lapatinib in breast cancer
-
Cameron DA, Stein S,. Drug insight: intracellular inhibitors of HER2-clinical development of lapatinib in breast cancer. Nat Clin Pract Oncol. 2008; 9: 512-520.
-
(2008)
Nat Clin Pract Oncol.
, vol.9
, pp. 512-520
-
-
Cameron, D.A.1
Stein, S.2
-
16
-
-
33845886440
-
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
-
DOI 10.1056/NEJMoa064320
-
Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006; 355: 2733-2743. (Pubitemid 46021510)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.26
, pp. 2733-2743
-
-
Geyer, C.E.1
Forster, J.2
Lindquist, D.3
Chan, S.4
Romieu, C.G.5
Pienkowski, T.6
Jagiello-Gruszfeld, A.7
Crown, J.8
Chan, A.9
Kaufman, B.10
Skarlos, D.11
Campone, M.12
Davidson, N.13
Berger, M.14
Oliva, C.15
Rubin, S.D.16
Stein, S.17
Cameron, D.18
-
17
-
-
46449113024
-
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer
-
Gomez HL, Doval DC, Chavez MA, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol. 2008; 26: 2999-3005.
-
(2008)
J Clin Oncol.
, vol.26
, pp. 2999-3005
-
-
Gomez, H.L.1
Doval, D.C.2
Chavez, M.A.3
-
18
-
-
33750310901
-
REporting recommendations for tumor MARKer prognostic studies (REMARK)
-
DOI 10.1007/s10549-006-9242-8
-
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM,. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat. 2006; 100: 229-235. (Pubitemid 44631925)
-
(2006)
Breast Cancer Research and Treatment
, vol.100
, Issue.2
, pp. 229-235
-
-
McShane, L.M.1
Altman, D.G.2
Sauerbrei, W.3
Taube, S.E.4
Gion, M.5
Clark, G.M.6
-
19
-
-
0037268795
-
The emerging role of monitoring serum HER-2/neu oncoprotein levels in women with metastatic breast cancer
-
DOI 10.1309/TY6M-DWB0-G2BU-6D5F
-
Carney WP,. The emerging role of monitoring serum HER-2/neu oncoprotein levels in women with metastatic breast cancer. Lab Medicine. 2003; 34: 58-64. (Pubitemid 36197260)
-
(2003)
Laboratory Medicine
, vol.34
, Issue.1
, pp. 58-64
-
-
Carney, W.P.1
-
20
-
-
33644528230
-
Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies
-
Esteva FJ, Cheli CD, Fritsche H, et al. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res. 2005; 7: R436-R443.
-
(2005)
Breast Cancer Res.
, vol.7
-
-
Esteva, F.J.1
Cheli, C.D.2
Fritsche, H.3
-
21
-
-
14644401104
-
Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: Association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate
-
DOI 10.1093/annonc/mdi059
-
Fornier MN, Seidman AD, Schwartz MK, et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol. 2005; 16: 234-239. (Pubitemid 40309302)
-
(2005)
Annals of Oncology
, vol.16
, Issue.2
, pp. 234-239
-
-
Fornier, M.N.1
Seidman, A.D.2
Schwartz, M.K.3
Ghani, F.4
Thiel, R.5
Norton, L.6
Hudis, C.7
-
22
-
-
63749132329
-
Utility of serum HER2 extracellular domain assessment in clinical decision making: Pooled analysis of four trials of trastuzumab in metastatic breast cancer
-
Lennon S, Barton C, Banken L, et al. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. J Clin Oncol. 2009; 27: 1685-1693.
-
(2009)
J Clin Oncol.
, vol.27
, pp. 1685-1693
-
-
Lennon, S.1
Barton, C.2
Banken, L.3
-
23
-
-
73949125361
-
Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study
-
Finn RS, Gagnon R, Di LA, Press MF, Arbushites M, Koehler M,. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study. J Clin Oncol. 2009; 27: 5552-5558.
-
(2009)
J Clin Oncol.
, vol.27
, pp. 5552-5558
-
-
Finn, R.S.1
Gagnon, R.2
Di, L.A.3
Press, M.F.4
Arbushites, M.5
Koehler, M.6
-
24
-
-
52049111595
-
Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor
-
Witters L, Scherle P, Friedman S, et al. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Cancer Res. 2008; 68: 7083-7089.
-
(2008)
Cancer Res.
, vol.68
, pp. 7083-7089
-
-
Witters, L.1
Scherle, P.2
Friedman, S.3
-
25
-
-
36849055007
-
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2-overexpressing breast cancer: A phase I dose-escalation study
-
DOI 10.1200/JCO.2007.11.7960
-
Modi S, Stopeck AT, Gordon MS, et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol. 2007; 25: 5410-5417. (Pubitemid 350232217)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.34
, pp. 5410-5417
-
-
Modi, S.1
Stopeck, A.T.2
Gordon, M.S.3
Mendelson, D.4
Solit, D.B.5
Bagatell, R.6
Ma, W.7
Wheler, J.8
Rosen, N.9
Norton, L.10
Cropp, G.F.11
Johnson, R.G.12
Hannah, A.L.13
Hudis, C.A.14
|